The IBL was badly affected due to the Corona epidemic. After the removal of restrictions related to Corona, the company’s business is once again back on track. Looking at the condition of the last eight quarters, the company’s sales have grown by more than 400 percent. The company had a loss of about Rs 5.3 crore in the June 2020 quarter, while the company made a profit of Rs 1.6 crore in the March 2022 quarter.
On June 8, 2022, the company’s stock reached Rs 41.20 on BSE, its 52-week high. Also this is its all time high level. Its 52-week low is Rs 8.42. On June 2, 2022, its two fully owned subsidiaries, IBL Healthcare Private Limited and HSL Agri Solutions Private Limited, were converted into Public Limited. After this their name has been changed to IBL Healthcare Limited and HSL Agri Solutions Limited.
The company is currently trading at 32.63 times TTM PE while the industry PE is 46.26 times. The company’s ROE stood at 18.38% and ROCE 20.46% in FY 2022. Indrayani Biotech Ltd shares were trading at Rs 39.80, down 1.85 per cent at 10 am.
This article is powered by Dalal Street Investment Journal, India’s No. 1 investment magazine. Click here for regular updates on Winning Stocks and Recommendations.
(Disclaimer: This above is third party content and TIL hereby disclaims any and all warranties, express or implied, relating to the same. TIL does not guarantee, vouch for or endorse any of the above content or its accuracy nor is responsible for it in any manner whatsoever. The content does not constitute any investment advice or solicitation of any kind. Users are advised to check with certified experts before taking any investment decision and take all steps necessary to ascertain that any information and content provided is correct, updated and verified.)